The prefilled syringes market is estimated to be worth over USD 2.5 billion in 2030, predicts Roots Analysis

Roots Analysis has done a detailed study on “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this link

 

Key Market Insights

• Eminent representatives from companies across the world attest to the fact that there is growing interest in the digital therapeutics market, highlighting the prevalent and anticipated trends in R&D and adoption
• Over 100 industry players are engaged in evaluating the potential of several prescription (validated through clinical research) digital therapeutic solutions to prevent / treat various chronic diseases
• The pipeline features a variety of digital health applications and therapy solutions that are in different stages of development, being investigated for diverse purposes, across a wide-range of clinical conditions
• These solutions have demonstrated applicability across more than 20 therapeutic areas; several products have been marketed / approved for the treatment or prevention of mental health problems and metabolic disorders
• In pursuit of a competitive edge, digital therapeutic solution developers are focusing on the integration of advanced features into their respective products and affiliated offerings
• In the last few years, over 220 clinical trials evaluating the potential benefits of digital therapeutics in close to 80,000 patients, have been registered; most of these were / are being conducted at various centers in the US
• Apart from the clinical benefit, cost is another key determinant of the acceptance and adoption of such novel interventions; pricing strategy matrix is likely to assist players to evaluate competitive market prices for solutions
• To support the ongoing innovation in this field, several private and public investors have made substantial capital investments, amounting to approximately USD 1.7 billion, in various initiatives of stakeholders
• The growing interest in this field is reflected by the increase in partnership activity, involving both international and indigenous stakeholders, across different geographical marketplaces
• In order to promote the adoption of proprietary digital health solutions, developers are actively exploring various marketing strategies in order to highlight key features of their products across a number of platforms
• Several digital monitoring / diagnostic solutions are also available to manage / diagnose patients for various chronic diseases; specifically, these remote monitoring solutions have gained interest during COVID-19
• Given the rising incidence of chronic clinical conditions and a growing pipeline of modern medicines to treat such diseases, the market for evidence-based digital therapeutics is poised to grow at a CAGR of ~20% till 2030
• The projected market opportunity is anticipated to be well-distributed across different therapeutic areas, distribution channels and key geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html

 

Table of Contents

 

1.         PREFACE                    

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1        Chapter Overview

3.2.       Digitization in the Healthcare Sector

3.3.       Next-Generation Healthcare Solutions

 

3.4.       Key Concepts Associated with Digital Health Solutions

3.4.1.    Cognitive Behavioral Therapy (CBT)

3.4.2.    Internet of Things (IoT)

3.4.3.    Big Data

3.4.4.    Artificial Intelligence (AI)

3.4.5.    Gamification

 

3.5.       Overview of Digital Therapeutics

3.5.1.    Key Strategic Initiatives

3.5.1.1. Digital Therapeutics Alliance (DTA)

3.5.1.2. Personal Connected Health (PCH) Alliance

3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)

3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)

3.5.1.5. National Health Service (NHS) Guidelines

3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics

 

3.5.2.    Product Development and Commercialization Path for Digital Therapeutics

3.5.2.1. Discovery and Preclinical Phase

3.5.2.2. Clinical Trials and Validation

3.5.2.3. Involving Insurance Providers / Payers

3.5.2.4. Distribution and Marketing

 

4.         CURRENT MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Digital Therapeutics: Overall Market Landscape

4.2.1.    Analysis by Status of Development

4.2.2.    Analysis by Type of Solution

4.2.3.    Analysis by Type of Therapy     

4.2.4.    Analysis by Purpose of Solution

4.2.5.    Analysis by Target Disease Indication(s)

4.2.6.    Analysis by Therapeutic Area

4.2.7.    Analysis by Target Population

 

4.3.       Digital Therapeutics: Additional Information

4.3.1.    Analysis by Prescription Requirement

4.3.2.    Analysis by Duration of Course

4.3.3.    Analysis by Cost of Solution

 

4.4.       Digital Therapeutics: List of Developers

4.4.1.    Analysis by Year of Establishment

4.4.2.    Analysis by Company Size

4.4.3.    Analysis by Type of Business Model

4.4.4.    Analysis by Location of Headquarters

 

4.5.       Leading Developers: Analysis by Number of Digital Therapeutics Solutions

4.6.       Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size

4.7.       Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area

4.8.       Tree Map Representation: Analysis by Therapeutic Area and Company Size

4.9.       World Map Representation: Analysis of Regional Activity

4.10.     Digital Therapeutics: Information on Additional Companies

 

5.         PRODUCT COMPETITIVENESS ANALYSIS

5.1.       Chapter Overview

5.2.       Methodology

5.3.       Assumptions / Key Parameters

5.4.       Key Therapeutic Areas

5.4.1.    Cardiovascular Disorders

5.4.1.1. Product Competitiveness Analysis

 

5.4.2.    Mental Health Problems

5.4.2.1. Product Competitiveness Analysis

 

5.4.3.    Metabolic Disorders     

5.4.3.1. Product Competitiveness Analysis

 

5.4.4.    Neurological Disorders

5.4.4.1. Product Competitiveness Analysis

 

5.4.5.    Substance Use Disorders

5.4.5.1. Product Competitiveness Analysis

 

5.4.6.    Other Therapeutic Areas

5.4.6.1. Product Competitiveness Analysis

 

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Akili Interactive

6.2.1     Company Overview

6.2.2.    Product Portfolio

6.2.3.    Recent Developments and Future Outlook

 

6.3.       Big Health

6.3.1.    Company Overview

6.3.2.    Product Portfolio

6.3.3.    Recent Developments and Future Outlook

 

6.4.       dreem

6.4.1.    Company Overview

6.4.2.    Product Portfolio

6.4.3.    Recent Developments and Future Outlook

 

6.5        Kaia Health

6.5.1.    Company Overview

6.5.2.    Product Portfolio

6.5.3.    Recent Developments and Future Outlook         

 

6.6.       Mindmaze

6.6.1.    Company Overview

6.6.2.    Product Portfolio

6.6.3.    Recent Developments and Future Outlook

 

6.7.       Omada Health

6.7.1.    Company Overview

6.7.2.    Product Portfolio

6.7.3.    Recent Developments and Future Outlook         

 

6.8.       Pear Therapeutics

6.8.1.    Company Overview

6.8.2.    Product Portfolio

6.8.3     Recent Developments and Future Outlook         

 

6.9.       Vida Health

6.9.1.    Company Overview

6.9.2.    Product Portfolio

6.9.3.  &nb